EUVIMEDEUVIMED entdecken
Open Access

CD4‐ and CD8 ‐to‐Total Lymphocyte Ratios to Guide Rabbit Anti‐Thymocyte Globulin Induction in Kidney Transplant Recipients: A Single‐Center Feasibility Study

I-Ru Chen iD, Ping-Chin Lai iD, Chiu-Ching Huang, Huey-Liang Kuo iD, Chang-Cheng Jiang, Chia-Hui Chou, Chao-Hsiang Chang, Chi-Ping Huang, Chin-Chung Yeh, Po-Jen Hsiao iD, Guan-Heng Chen, Yu-Cyuan Hong und 1 weitere

Nephrology · 2026-08 · 31 (8)

DOI: 10.1111/nep.70267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology, online erschienen am 10.08.2026. Verfasst von I-Ru Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and the Kidney Institute, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Kidney Transplantation, Antilymphocyte Serum, Graft Rejection, Immunosuppressive Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Rabbit anti‐thymocyte globulin (rATG) is widely used for induction immunosuppression in kidney transplantation, but conventional dosing is largely weight based and may not reflect dynamic interindividual immune responses. We aimed to evaluate a predefined, individualized dosing strategy guided by peripheral CD4‐to‐total lymphocyte (CD4/TLC) and CD8‐to‐total lymphocyte (CD8/TLC) ratios and to assess its feasibility and 1‐year outcomes.

Methods

In this single‐center retrospective cohort study conducted in Taiwan from 2018 to 2024, 76 adult kidney transplant recipients received rATG titrated by serial flow cytometry to a predefined target of both CD4/TLC and CD8/TLC ratios < 10%. We evaluated cumulative rATG exposure, lymphocyte‐subset response, for‐cause biopsy‐proven acute rejection (BPAR), graft function, graft loss, hospitalization‐requiring infections, and mortality over 1 year.

Results

The median cumulative rATG dose was 1.2 mg/kg (IQR, 1.1–1.5; maximum, 3.8). Thirty‐eight recipients (50.0%) reached the immunologic target after a single intraoperative dose (1–1.5 mg/kg). At 1 year, for‐cause BPAR occurred in 1 recipient (1.3%), mean serum creatinine was 1.20 mg/dL, and no graft loss occurred. Seventeen recipients experienced hospitalization‐requiring infections, accounting for 22 episodes. No CMV disease or biopsy‐proven BK virus nephropathy was observed. Four recipients (5.3%) died, including two deaths related to opportunistic fungal infections.

Conclusion

CD4/TLC‐ and CD8/TLC‐guided rATG dosing was feasible and achieved predefined immunologic targets with low cumulative rATG exposure in this cohort. These findings support prospective controlled studies to evaluate the clinical utility, safety, and comparative effectiveness of this individualized dosing strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAntilymphocyte SerumGraft RejectionImmunosuppressive AgentsCD4-CD8 RatioCD8-Positive T-LymphocytesHumansFeasibility StudiesFemaleMaleMiddle AgedRetrospective StudiesAnimalsRabbitsAdultGraft SurvivalTreatment OutcomeTaiwan

Stichwörter der Autor:innen

T‐cell subsetsbiomarker‐guided dosinginduction immunosuppressionkidney transplantationrabbit anti‐thymocyte globulin

Substanzen

Antilymphocyte SerumImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Nephrology and the Kidney Institute, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Department of Urology, China Medical University Hospital, Taichung, Taiwan.
  • Department of Urology, China Medical University Hsinchu Hospital, Hsinchu, Taiwan.

ORCID-Profile: I-Ru Chen, Ping-Chin Lai, Huey-Liang Kuo, Po-Jen Hsiao

Zitieren

APA

Chen, I. R., Lai, P. C., Huang, C. C., Kuo, H. L., Jiang, C. C., Chou, C. H., Chang, C. H., Huang, C. P., Yeh, C. C., Hsiao, P. J., Chen, G. H., Hong, Y. C., & Chang, Y. H. (2026). CD4‐ and CD8 ‐to‐Total Lymphocyte Ratios to Guide Rabbit Anti‐Thymocyte Globulin Induction in Kidney Transplant Recipients: A Single‐Center Feasibility Study. Nephrology, 31(8). https://doi.org/10.1111/nep.70267

Vancouver

Chen IR, Lai PC, Huang CC, Kuo HL, Jiang CC, Chou CH, et al. CD4‐ and CD8 ‐to‐Total Lymphocyte Ratios to Guide Rabbit Anti‐Thymocyte Globulin Induction in Kidney Transplant Recipients: A Single‐Center Feasibility Study. Nephrology. 2026;31(8). doi:10.1111/nep.70267

BibTeX
@article{Chen2026,
  author = {Chen, I-Ru and Lai, Ping-Chin and Huang, Chiu-Ching and Kuo, Huey-Liang and Jiang, Chang-Cheng and Chou, Chia-Hui and Chang, Chao-Hsiang and Huang, Chi-Ping and Yeh, Chin-Chung and Hsiao, Po-Jen and Chen, Guan-Heng and Hong, Yu-Cyuan and Chang, Yi-Huei},
  title = {CD4‐ and CD8 ‐to‐Total Lymphocyte Ratios to Guide Rabbit Anti‐Thymocyte Globulin Induction in Kidney Transplant Recipients: A Single‐Center Feasibility Study},
  journal = {Nephrology},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1111/nep.70267}
}
Kostenlos starten →